Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release

Evidence for serotonin-catecholamine interactions

Cecil O. Lynch, Mahlon Johnson, William R. Crowley

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems. Quipazine (15 mg/kg, ip) significantly reduced LH and increased PRL when administered to ovariectomized rats. Associated with these changes, the depletion of dopamine seen after synthesis inhibition with α-methyl tyrosine was reduced by quipazine in the caudate nucleus and median eminence, suggesting a depression of dopaminergic activity. The depletion of norepinephrine in the median eminence was unaffected. In a second experiment, quipazine (1 μM) diminished the potassium-induced release of both norepinephrine and dopamine from fragments of medial basal hypothalamus, in vitro. Release from preoptic area was unaffected. These results suggest that central serotonergic systems may interact with noradrenergic and dopaminergic systems that regulate LH and PRL secretion, respectively.

Original languageEnglish (US)
Pages (from-to)1481-1487
Number of pages7
JournalLife Sciences
Volume35
Issue number14
DOIs
StatePublished - Oct 1 1984

Fingerprint

Quipazine
Serotonin Receptor Agonists
Luteinizing Hormone
Prolactin
Catecholamines
Serotonin
Median Eminence
Dopamine
Norepinephrine
Middle Hypothalamus
Preoptic Area
Caudate Nucleus
Tyrosine
Rats
Potassium
Experiments

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release : Evidence for serotonin-catecholamine interactions. / Lynch, Cecil O.; Johnson, Mahlon; Crowley, William R.

In: Life Sciences, Vol. 35, No. 14, 01.10.1984, p. 1481-1487.

Research output: Contribution to journalArticle

@article{4e36502c48a54460bd1b3234c538f80e,
title = "Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release: Evidence for serotonin-catecholamine interactions",
abstract = "The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems. Quipazine (15 mg/kg, ip) significantly reduced LH and increased PRL when administered to ovariectomized rats. Associated with these changes, the depletion of dopamine seen after synthesis inhibition with α-methyl tyrosine was reduced by quipazine in the caudate nucleus and median eminence, suggesting a depression of dopaminergic activity. The depletion of norepinephrine in the median eminence was unaffected. In a second experiment, quipazine (1 μM) diminished the potassium-induced release of both norepinephrine and dopamine from fragments of medial basal hypothalamus, in vitro. Release from preoptic area was unaffected. These results suggest that central serotonergic systems may interact with noradrenergic and dopaminergic systems that regulate LH and PRL secretion, respectively.",
author = "Lynch, {Cecil O.} and Mahlon Johnson and Crowley, {William R.}",
year = "1984",
month = "10",
day = "1",
doi = "10.1016/0024-3205(84)90165-6",
language = "English (US)",
volume = "35",
pages = "1481--1487",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Effects of the serotonin agonist, quipazine, on luteinizing hormone and prolactin release

T2 - Evidence for serotonin-catecholamine interactions

AU - Lynch, Cecil O.

AU - Johnson, Mahlon

AU - Crowley, William R.

PY - 1984/10/1

Y1 - 1984/10/1

N2 - The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems. Quipazine (15 mg/kg, ip) significantly reduced LH and increased PRL when administered to ovariectomized rats. Associated with these changes, the depletion of dopamine seen after synthesis inhibition with α-methyl tyrosine was reduced by quipazine in the caudate nucleus and median eminence, suggesting a depression of dopaminergic activity. The depletion of norepinephrine in the median eminence was unaffected. In a second experiment, quipazine (1 μM) diminished the potassium-induced release of both norepinephrine and dopamine from fragments of medial basal hypothalamus, in vitro. Release from preoptic area was unaffected. These results suggest that central serotonergic systems may interact with noradrenergic and dopaminergic systems that regulate LH and PRL secretion, respectively.

AB - The present study tested whether administration of the serotonin agonist, quipazine maleate, affects the secretion of luteinizing hormone (LH) and prolactin (PRL) and concomitantly, the activity of central noradrenergic and dopaminergic systems. Quipazine (15 mg/kg, ip) significantly reduced LH and increased PRL when administered to ovariectomized rats. Associated with these changes, the depletion of dopamine seen after synthesis inhibition with α-methyl tyrosine was reduced by quipazine in the caudate nucleus and median eminence, suggesting a depression of dopaminergic activity. The depletion of norepinephrine in the median eminence was unaffected. In a second experiment, quipazine (1 μM) diminished the potassium-induced release of both norepinephrine and dopamine from fragments of medial basal hypothalamus, in vitro. Release from preoptic area was unaffected. These results suggest that central serotonergic systems may interact with noradrenergic and dopaminergic systems that regulate LH and PRL secretion, respectively.

UR - http://www.scopus.com/inward/record.url?scp=0021207475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021207475&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(84)90165-6

DO - 10.1016/0024-3205(84)90165-6

M3 - Article

VL - 35

SP - 1481

EP - 1487

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 14

ER -